AR119942A1 - Tratamiento de hidradenitis con inhibidores de quinasa - Google Patents
Tratamiento de hidradenitis con inhibidores de quinasaInfo
- Publication number
- AR119942A1 AR119942A1 ARP200102525A ARP200102525A AR119942A1 AR 119942 A1 AR119942 A1 AR 119942A1 AR P200102525 A ARP200102525 A AR P200102525A AR P200102525 A ARP200102525 A AR P200102525A AR 119942 A1 AR119942 A1 AR 119942A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- hidradenitis
- treatment
- Prior art date
Links
- 208000002557 hidradenitis Diseases 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 2
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 abstract 2
- BUWBRTXGQRBBHG-MJBXVCDLSA-N FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F Chemical group FC1([C@@H](C1)C(=O)N1[C@H]2CN(C[C@@H]1CC2)C1=NC(=NC=C1)NC=1C=NN(C=1)C)F BUWBRTXGQRBBHG-MJBXVCDLSA-N 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- IUEWXNHSKRWHDY-PHIMTYICSA-N abrocitinib Chemical group C1[C@@H](NS(=O)(=O)CCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-PHIMTYICSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para tratar hidradenitis supurativa usando compuestos y análogos que inhiben determinadas quinasas, que incluyen la quinasa Janus (JAK). Reivindicación 2: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de Tyk2 / JAK1 es [(1S)-2,2-difluorociclo-propil][(1R,5S)-3-{2-[(1-metil-1H-pirazol-4-il)amino]pirimidin-4-il}-3,8-diazabiciclo[3.2.1]oct-8-il]metanona; o una sal de aquel aceptable desde el punto de vista farmacéutico. Reivindicación 5: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de JAK1 es N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}-propan-1-sulfonamida, o una sal de aquel aceptable desde el punto de vista farmacéutico. Reivindicación 6: El método de acuerdo con la reivindicación 1, caracterizado porque dicho inhibidor de Tyk2 es (1r,3r)-3-(cianometil)-3-(4-(6-(1-metil-1H-pirazol-4-il)pirazolo[1,5-a]pirazin-4-il)-1H-pirazol-1-il)ciclobutan-1-carbonitrilo, o una sal de aquel aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899133P | 2019-09-11 | 2019-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119942A1 true AR119942A1 (es) | 2022-01-19 |
Family
ID=72473596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102525A AR119942A1 (es) | 2019-09-11 | 2020-09-11 | Tratamiento de hidradenitis con inhibidores de quinasa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250032492A1 (es) |
| EP (1) | EP4028007B1 (es) |
| JP (1) | JP2021042204A (es) |
| KR (1) | KR20220059519A (es) |
| CN (1) | CN114667148A (es) |
| AR (1) | AR119942A1 (es) |
| AU (1) | AU2020347561A1 (es) |
| BR (1) | BR112022004221A2 (es) |
| CA (1) | CA3153676A1 (es) |
| ES (1) | ES3019413T3 (es) |
| IL (1) | IL291146A (es) |
| MX (1) | MX2022002995A (es) |
| NZ (1) | NZ786079A (es) |
| TW (1) | TWI846947B (es) |
| WO (1) | WO2021048736A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240162125A (ko) * | 2022-03-17 | 2024-11-14 | 화이자 인코포레이티드 | 한선염 치료를 위한 방법, 투여 레지멘, 및 조성물 |
| EP4665350A1 (en) * | 2023-02-16 | 2025-12-24 | Alumis Inc. | Methods of treating hidradenitis suppurativa |
| WO2025257327A1 (en) * | 2024-06-13 | 2025-12-18 | Almirall, S.A. | Therapeutic approaches for the management of hidradenitis suppurativa |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105008362B (zh) * | 2013-02-22 | 2017-06-06 | 辉瑞大药厂 | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物 |
| NO2721710T3 (es) * | 2014-08-21 | 2018-03-31 | ||
| WO2017143014A1 (en) * | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
| UA119835C2 (uk) * | 2016-02-24 | 2019-08-12 | Пфайзер Інк. | ПОХІДНІ ПІРАЗОЛО[1,5-а]ПІРАЗИН-4-ІЛУ ЯК JAK-ІНГІБІТОРИ |
| EP3848370B1 (en) * | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| JP7565798B2 (ja) * | 2018-03-30 | 2024-10-11 | インサイト・コーポレイション | 炎症性皮膚疾患のバイオマーカー |
| EP4424328A3 (en) * | 2018-03-30 | 2024-12-04 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
-
2020
- 2020-09-08 KR KR1020227011306A patent/KR20220059519A/ko not_active Ceased
- 2020-09-08 WO PCT/IB2020/058333 patent/WO2021048736A1/en not_active Ceased
- 2020-09-08 EP EP20771628.3A patent/EP4028007B1/en active Active
- 2020-09-08 NZ NZ786079A patent/NZ786079A/en unknown
- 2020-09-08 ES ES20771628T patent/ES3019413T3/es active Active
- 2020-09-08 CA CA3153676A patent/CA3153676A1/en active Pending
- 2020-09-08 MX MX2022002995A patent/MX2022002995A/es unknown
- 2020-09-08 AU AU2020347561A patent/AU2020347561A1/en active Pending
- 2020-09-08 US US17/641,127 patent/US20250032492A1/en active Pending
- 2020-09-08 BR BR112022004221A patent/BR112022004221A2/pt unknown
- 2020-09-08 CN CN202080078318.5A patent/CN114667148A/zh active Pending
- 2020-09-10 TW TW109131138A patent/TWI846947B/zh active
- 2020-09-10 JP JP2020151758A patent/JP2021042204A/ja active Pending
- 2020-09-11 AR ARP200102525A patent/AR119942A1/es unknown
-
2022
- 2022-03-06 IL IL291146A patent/IL291146A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020347561A1 (en) | 2022-04-14 |
| BR112022004221A2 (pt) | 2022-05-31 |
| EP4028007B1 (en) | 2025-03-26 |
| IL291146A (en) | 2022-05-01 |
| NZ786079A (en) | 2025-10-31 |
| ES3019413T3 (en) | 2025-05-20 |
| TWI846947B (zh) | 2024-07-01 |
| US20250032492A1 (en) | 2025-01-30 |
| MX2022002995A (es) | 2022-06-02 |
| JP2021042204A (ja) | 2021-03-18 |
| CA3153676A1 (en) | 2021-03-18 |
| WO2021048736A1 (en) | 2021-03-18 |
| CN114667148A (zh) | 2022-06-24 |
| EP4028007A1 (en) | 2022-07-20 |
| TW202123940A (zh) | 2021-07-01 |
| KR20220059519A (ko) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119942A1 (es) | Tratamiento de hidradenitis con inhibidores de quinasa | |
| HRP20201887T1 (hr) | LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K | |
| AR119210A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| NZ598907A (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | |
| JP2022184886A5 (es) | ||
| ZA201808534B (en) | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide | |
| PH12020551639A1 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| CL2008001364A1 (es) | Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos. | |
| PE20212186A1 (es) | Inhibidores de la via de jak1 para el tratamiento de trastornos relacionados con citoquinas | |
| JP2020504136A5 (es) | ||
| JP2015519401A5 (es) | ||
| EA201070013A1 (ru) | СОЛИ ИНГИБИТОРА ЯНУС-КИНАЗЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА | |
| NZ590922A (en) | Piperidine derivatives as jak3 inhibitors | |
| NZ611151A (en) | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors | |
| AU2015364335A1 (en) | Treatment of pemphigus | |
| EA202191903A1 (ru) | Антипролиферативные соединения и вторые активные агенты для комбинированного применения | |
| PH12023553203A1 (en) | Methods of treating b-cell malignancy using bcl-2 inhibitor | |
| UY31866A (es) | Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones | |
| BR112022022932A2 (pt) | Inibidor de vcp/p97 para o tratamento do câncer | |
| RU2014143213A (ru) | Соединения ингибитора тирозинкиназы и их применение | |
| AR120809A1 (es) | Tratamiento de colitis ulcerosa con inhibidores de quinasa | |
| MX2024003134A (es) | Metodos de tratamiento del cancer utilizando una combinacion de inhibidores de btk e inhibidores de pi3 quinasa. | |
| RU2022119586A (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ | |
| MX2023010174A (es) | Metodos para el tratamiento de vitiligo. |